Loading...
01/09 22:10
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary shows mixed signals: improvements in gross margins and operating expenses are positive, but ongoing losses and cash depletion are concerning. The Q&A reveals potential growth in indium phosphide demand, but uncertainties in export licenses and permitting delays pose risks. The company's optimistic guidance and backlog could boost stock, but lack of clarity on license issues tempers this optimism. The absence of a market cap makes it hard to predict volatility, but overall, the sentiment is balanced, leading to a neutral stock price prediction.
Revenue $18.0 million in Q2 2025, compared to $19.4 million in Q1 2025 and $27.9 million in Q2 2024. This represents a year-over-year decrease of approximately 35.5%, primarily due to slower export permit processing and sluggish demand in China.
Indium Phosphide Revenue $3.6 million in Q2 2025, driven by PON and data center applications in China. Growth in AI-related demand for indium phosphide substrates in China contributed positively.
Gallium Arsenide Revenue $6.2 million in Q2 2025. Growth in wireless business in China contributed positively, despite sluggish demand and slower export permit processing.
Germanium Substrates Revenue $1.5 million in Q2 2025, driven by satellite solar cell applications in China. However, the market remains price-sensitive, and export permits for sales outside China are difficult to obtain.
Raw Material Joint Venture Revenue $6.7 million in Q2 2025, a decline of approximately $1.6 million compared to Q1 2025, due to economic climate and changes in customer service model mix.
Non-GAAP Gross Margin 8.2% in Q2 2025, compared to negative 6.1% in Q1 2025 and 27.6% in Q2 2024. The improvement from Q1 is attributed to manufacturing process and efficiency improvements, while the year-over-year decline is due to lower revenue and higher costs.
GAAP Gross Margin 8.0% in Q2 2025, compared to negative 6.4% in Q1 2025 and 27.4% in Q2 2024. Similar reasons as non-GAAP gross margin changes.
Non-GAAP Operating Expense $7.6 million in Q2 2025, compared to $8.5 million in Q1 2025 and $8.9 million in Q2 2024. The decrease is due to cost control measures in a difficult climate.
GAAP Operating Expense $8.2 million in Q2 2025, compared to $9.0 million in Q1 2025 and $9.5 million in Q2 2024. Similar reasons as non-GAAP operating expense changes.
Non-GAAP Operating Loss $6.1 million in Q2 2025, compared to $9.6 million in Q1 2025 and $1.2 million in Q2 2024. The improvement from Q1 is due to cost control and gross margin recovery, while the year-over-year decline is due to lower revenue.
GAAP Operating Loss $6.7 million in Q2 2025, compared to $10.3 million in Q1 2025 and $1.9 million in Q2 2024. Similar reasons as non-GAAP operating loss changes.
Non-GAAP Net Loss $6.4 million or $0.15 per share in Q2 2025, compared to $8.2 million or $0.19 per share in Q1 2025 and $0.8 million or $0.02 per share in Q2 2024. The improvement from Q1 is due to cost control and gross margin recovery, while the year-over-year decline is due to lower revenue.
GAAP Net Loss $7.0 million or $0.16 per share in Q2 2025, compared to $8.8 million or $0.20 per share in Q1 2025 and $1.5 million or $0.04 per share in Q2 2024. Similar reasons as non-GAAP net loss changes.
Cash and Cash Equivalents $35.1 million as of June 30, 2025, a decrease of $3.1 million from $38.2 million as of March 31, 2025, due to operating losses and other factors.
Depreciation and Amortization $2.5 million in Q2 2025.
Stock Compensation $0.6 million in Q2 2025.
Net Inventory $80.1 million in Q2 2025, a decrease of approximately $300,000 from Q1 2025, reflecting ongoing efforts to reduce inventory levels.
Indium Phosphide Substrates: Revenue increased in Q2, driven by AI-related demand in China and initial export orders outside China. Revenue expected to grow by 30% or more in Q3.
Gallium Arsenide Substrates: Revenue grew in Q2, with continued growth expected in Q3. Export permits delayed shipments outside China, but permit processing improved in July.
Germanium Substrates: Revenue grew in Q2 due to satellite solar cell applications in China. However, sales are expected to decline in Q3 due to export permit challenges and price sensitivity.
China Data Center Market: Accelerating growth in cloud and data center connectivity, with significant efforts to develop domestic sources for lasers. Indium phosphide sales within China nearly doubled in Q2.
Wireless Market in China: Revenue grew in Q2, with continued growth expected in Q3. Market expansion was measured, focusing on yield and efficiency.
Gross Margin Improvement: Non-GAAP gross margin improved to 8.2% in Q2 from negative 6.1% in Q1. Further improvement expected in Q3.
Operating Expenses: Non-GAAP operating expenses reduced to $7.6 million in Q2 from $8.5 million in Q1. Cost control remains a focus.
Export Permit Process: Delays in export permits for gallium arsenide and indium phosphide impacted revenue. Progress made in July, with additional permits expected in Q3.
Tongmei IPO in China: IPO application remains active, with Tongmei considered a strong candidate despite geopolitical challenges.
Export Restrictions: The company faces delays in obtaining export permits for gallium arsenide and indium phosphide, which has impacted revenue. The permitting process has been slower than expected, particularly for gallium arsenide, causing shipment delays and revenue shortfalls.
Geopolitical Environment: The geopolitical environment, including trade restrictions imposed by the Chinese government, presents near-term headwinds for the business. These restrictions explicitly target materials used for military applications, complicating the export process.
Demand Sluggishness in China: Demand for gallium arsenide in China was sluggish in Q2, with customers taking a cautious approach to ordering and holding inventory. This has negatively impacted revenue growth.
Germanium Substrate Challenges: The germanium substrate business faces challenges due to high raw material costs and difficulties in obtaining export permits for sales outside of China. This has constrained gross margins and is expected to lead to lower sales in the second half of the year.
Economic Climate Impact: The economic climate has negatively impacted the company's raw material joint ventures, leading to a decline in revenue from these operations.
Inventory Management: The company is working to reduce its high inventory levels, which stood at $80.1 million in Q2. This remains a focus area for improvement.
Q3 Revenue: Expected to grow sequentially to be in the range of $19.0 million to $21.0 million. This includes a modest contribution from indium phosphide and gallium arsenide for customers outside of China and revenue for which permits are currently available.
Gross Margin: Expected to improve again in Q3, reaching the low mid- to mid-teens.
Non-GAAP Net Loss: Projected to be in the range of $0.11 to $0.13.
GAAP Net Loss: Projected to be in the range of $0.13 to $0.15.
Indium Phosphide Revenue: Expected to grow by 30% or more in Q3, driven by applications in PON, data center connectivity, and various indium phosphide-based sensors.
Gallium Arsenide Revenue: Expected to grow sequentially in Q3, supported by improved permit processing and growth in wireless business in China.
Germanium Revenue: Expected to decline in Q3 and remain at lower levels through the second half of the year.
Raw Material Business: Expected to remain approximately flat in Q3 compared to the prior quarter.
The selected topic was not discussed during the call.
The earnings call indicates strong growth in indium phosphide revenue, driven by global demand, particularly outside China. Despite a non-GAAP loss, the company is optimistic about improving gross margins and expanding capacity. The backlog for indium phosphide has more than doubled, and customer interest is high due to product quality. The Q&A session revealed positive analyst sentiment and confidence in future growth. However, the company's cash position has decreased, and some management responses lacked clarity. Overall, the positive growth outlook and strong demand outweigh the financial concerns, suggesting a positive stock price reaction.
The earnings call summary shows mixed signals: improvements in gross margins and operating expenses are positive, but ongoing losses and cash depletion are concerning. The Q&A reveals potential growth in indium phosphide demand, but uncertainties in export licenses and permitting delays pose risks. The company's optimistic guidance and backlog could boost stock, but lack of clarity on license issues tempers this optimism. The absence of a market cap makes it hard to predict volatility, but overall, the sentiment is balanced, leading to a neutral stock price prediction.
The earnings call reveals significant challenges: a 15% revenue drop, negative gross margins due to yield issues, and geopolitical/export restrictions impacting operations. Despite management's optimism about resolving yield problems, their vague responses in the Q&A raise doubts. The absence of a share repurchase program and worsening financial losses further contribute to a negative outlook. Given the critical risks and lack of positive catalysts, the stock is likely to experience a strong negative reaction (>8% decline) over the next two weeks.
The earnings call reveals mixed signals. While revenue increased and long-term growth is expected, short-term challenges like reduced gross margins, increased operating expenses, and significant net losses are concerning. The Q&A highlights potential export restrictions impacting Q1 sales and unclear management responses, further contributing to uncertainty. The absence of a share repurchase program and customer concentration risk add to the negative outlook. Despite some positive aspects, such as growth in fiscal year revenue and optimism for 2025, the immediate negative factors are likely to outweigh, predicting a negative stock price reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
